Abstract
Advanced colorectal cancer is the first tumor type for which an antiangiogenic agent, namely bevacizumab, has been approved by the Food and Drug Administration for therapy in humans; it has been in use since February 2004. This review paper summarizes and discusses the results obtained with this agent and highlights the main open or controversial issues on antiangiogenic therapy, taking into account that the clinical results obtained are below the expectations, particularly in the adjuvant setting.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Colorectal Neoplasms / blood supply*
-
Colorectal Neoplasms / drug therapy*
-
Humans
-
Neovascularization, Pathologic / drug therapy
-
Randomized Controlled Trials as Topic
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab